Clinical Trial

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced…

3 months ago

MMI Completes World’s First Robotic Microsurgical Intracranial Brain Surgery

First-in-human cases lay the foundation for the next frontier in robotic microsurgeryJACKSONVILLE, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MMI…

3 months ago

Daytona Beach Clinical Trial Site Now Enrolling for Heart Protection Study

DAYTONA BEACH, FLORIDA / ACCESS Newswire / October 6, 2025 / Arrow Clinical Trials, a physician-owned clinical research site based…

3 months ago

GATC Health’s Derisq™ AI Report Introduced at Invitation-Only Webinar Hosted by ASTR Partners

Biotech, pharma and finance leaders attend “Rethinking Risk – How AI Can Optimize Biotech Capital Allocation”IRVINE, Calif., Oct. 06, 2025…

3 months ago

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or…

3 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support…

3 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer…

3 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® 

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients…

3 months ago

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage…

3 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were…

3 months ago